Zymeworks Inc (ZYME) Q4 2025 Earnings Call Transcript

Why It Matters

The results illustrate BMS’s successful transition toward newer, higher‑margin products, mitigating loss‑of‑exclusivity pressures and supporting a bullish outlook for investors.

Key Takeaways

• Growth portfolio generates $7.4B, 15% YoY increase
• Total Q4 revenue flat at $12.5B
• Eliquis revenue rises 6% despite margin pressure
• 2026 revenue guidance $46‑47.5B, legacy decline 12‑16%
• Breyanzi gains FDA approval for marginal zone lymphoma

Pulse Analysis

Bristol‑Myers Squibb’s fourth‑quarter earnings underscore a pivotal shift in its revenue composition. While total sales held steady at $12.5 billion, the company’s growth portfolio now accounts for nearly 60% of that total, driven by double‑digit gains in oncology and cardiovascular franchises. This diversification cushions the impact of loss‑of‑exclusivity on legacy drugs, yet margin compression persists as higher‑priced products like Eliquis and Revlimid alter the mix, pulling gross margin down to 71.9%. Investors are watching how the firm balances these dynamics while maintaining earnings momentum.

Strategic cost‑management initiatives further bolster the outlook. BMS achieved a $1 billion productivity gain in 2025 and is on track for an additional $1 billion in savings through 2027, complementing a $10 billion accelerated debt reduction. The company also leveraged a 40% wholesale acquisition cost cut for Eliquis, expanding patient access and offsetting pricing pressure. Meanwhile, the pipeline is gaining traction: Breyanzi’s new indication for marginal‑zone lymphoma adds a fifth CAR‑T indication, and six registrational studies are slated for the second half of 2026, spanning hematology, oncology, and rare diseases. These developments aim to sustain top‑line growth and reinforce BMS’s position in high‑value therapeutic areas.

Looking ahead, BMS projects 2026 revenue between $46 billion and $47.5 billion, with Eliquis expected to grow 10‑15% despite looming generic competition in ex‑U.S. markets. The anticipated 12‑16% decline in legacy sales reflects ongoing patent expirations, but the firm’s emphasis on innovative biologics and oral CELMoD agents suggests a resilient growth trajectory. Analysts will weigh the guidance against execution risk, particularly the timing of pipeline readouts and the effectiveness of pricing strategies, as the company strives to deliver sustainable shareholder value into the 2030s.